Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical Policyeocco Krystexxa prior auth Coverage Update | OpenP…
    Ask Trek AI about this page
    CurrenteoccoPolicy IC-0158

    Krystexxa (pegloticase) (Intravenous) — Prior Authorization and Coverage Criteria

    Customize your policy alerts

    Sign up for eocco Policy IC-0158 alerts

    Get alerted when Policy IC-0158 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, approval and renewal criteria, billing codes, and covered diagnoses for use of Krystexxa (pegloticase) for chronic gout in adults.

    Policy Summary
    Payereocco
    PolicyKrystexxa (pegloticase) (Intravenous) — Coverage Criteria
    Policy CodePolicy IC-0158
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization with documentation of baseline serum uric acid ≥ 7 mg/dL; initial approval is valid for 6 months and renewals up to 12 months with labs showing serum uric acid ≤ 6 mg/dL prior to infusion.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 moInitial prior authorization length
    12 moRenewal prior authorization length
    16/28dMax billable HCPCS units
    8 mg q2wRecommended dosing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J2507HCPCS billing code
    ~70+Covered ICD-10 codes (appendix)

    Coverage Criteria for Krystexxa (pegloticase)

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Initial Approval — adult candidacy and safety: Member is at least 18 years of age AND member does NOT have any FDA-labeled contraindications to Krystexxa (for example: glucose-6-phosphate dehydrogenase [G6PD] deficiency or history of serious hypersensitivity to Krystexxa or any of its components) AND documentation of baseline serum uric acid level ≥ 7 mg/dL (current lab reports required for renewal)
    Universal therapy conditions: Therapy must not be given in combination with other urate-lowering therapies (e.g., allopurinol, febuxostat, probenecid)
    Chronic gout refractory criteria: Documented contraindication, intolerance, or clinical failure (inability to reduce serum uric acid to < 6 mg/dL) after a minimum 3-month trial on maximum tolerated dose of xanthine oxidase inhibitors (e.g., allopurinol or febuxostat) or uricosuric agents (e.g., probenecid) AND used in combination with methotrexate OR as a single agent if methotrexate is contraindicated or not clinically appropriate AND member has one of the following: 2 or more gout flares per year inadequately controlled by colchicine/NSAIDs/oral or injectable corticosteroids OR at least one non-resolving subcutaneous tophus OR radiographic evidence of gout-attributable damage

    Continuation Therapy / Renewal — Renewal allowed when ALL of the following are met

    Renewal allowed when ALL of the following are met:

    Continuation criteria: Member continues to meet the universal and indication-specific criteria identified for initial approval AND demonstrates disease response to treatment (e.g., reduction of symptoms or reduction of tophi) AND has absence of unacceptable toxicity to the drug (examples include anaphylaxis, infusion reactions, exacerbation of congestive heart failure, hemolytic reactions) AND documentation of serum uric acid level ≤ 6 mg/dL prior to scheduled infusion AND continuation of therapy is necessary to maintain response/remission

    General coverage conditions — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Diagnosis: Member has one of the ICD-10 diagnosis codes listed in Appendix 1 (M1A.* series and other listed codes)
    Medicare compliance: For Medicare members, applicable CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) must be followed where applicable

    Therapy is excluded when administered in combination with other urate‑lowering therapies. Examples specifically listed include allopurinol, febuxostat, and probenecid — Krystexxa should not be given concurrently with these agents.

    For the Medicare Part B covered diagnosis codes section, this document lists N/A; no specific Medicare Part B diagnosis codes are provided in this policy segment.

    Use of Krystexxa is not supported in patients with FDA‑labeled contraindications. The policy specifically cites glucose‑6‑phosphate dehydrogenase (G6PD) deficiency and a history of serious hypersensitivity reaction to Krystexxa or any of its components as contraindications.

    Billing Codes and Covered Diagnoses

    HCPCS CodeHCPCSCovered
    J2507Injection, pegloticase, 1 mg; 1 billable unit = 1 mg
    NDCsNDC
    75987-0058-xxKrystexxa 8 mg/50 mL (0.16 mg/mL) Ready-to-Use single-dose vial NDC
    75987-0080-xxKrystexxa 8 mg/mL To-be-Diluted single-dose vial NDC
    Covered ICD-10 Diagnosis Codes (partial list shown)ICD-10Covered
    M1A.00X0Idiopathic chronic gout, unspecified site, without tophus (tophi).
    M1A.00X1Idiopathic chronic gout, unspecified site, with tophus (tophi).
    M1A.0110Idiopathic chronic gout, right shoulder, without tophus (tophi).
    M1A.0111Idiopathic chronic gout, right shoulder, with tophus (tophi).
    M1A.0120Idiopathic chronic gout, left shoulder, without tophus (tophi).
    Covered ICD-10 Diagnosis Codes (Appendix 1)ICD-10Covered
    M1A.3210Chronic gout due to renal impairment, unspecified shoulder, with tophus (tophi).
    M1A.3211Chronic gout due to renal impairment, right elbow, without tophus (tophi).
    M1A.3220Chronic gout due to renal impairment, left elbow, without tophus (tophi).
    M1A.3221Chronic gout due to renal impairment, left elbow, with tophus (tophi).
    M1A.3290Chronic gout due to renal impairment, unspecified elbow, without tophus (tophi).
    M1A.3291Chronic gout due to renal impairment, unspecified elbow, with tophus (tophi).
    M1A.3310Chronic gout due to renal impairment, right wrist, without tophus (tophi).
    M1A.3311Chronic gout due to renal impairment, right wrist, with tophus (tophi).
    M1A.3320Chronic gout due to renal impairment, left wrist, without tophus (tophi).
    M1A.3321Chronic gout due to renal impairment, left wrist, with tophus (tophi).
    1–10 of 90
    1/9
    Serum uric acid (baseline and pre-infusion)
    Baseline serum uric acidDocumentation of baseline serum uric acid level ≥ 7 mg/dL (current lab reports required)
    Pre-infusion / Renewal serum uric acidDocumentation of serum uric acid level ≤ 6 mg/dL prior to scheduled infusion for renewals
    Lab documentation requirementCurrent laboratory reports must be provided for initial authorization and for renewals

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior authorization validity and renewals

    Prior authorization is required. Initial authorization is valid for 6 months (180 days); renewals may be granted every 12 months (365 days).

    Prior Authorization

    Provide covered ICD-10 diagnosis code

    Include an appropriate ICD-10 diagnosis code from Appendix 1 (e.g., M1A.* series) on the prior authorization request; Medicare providers must also follow any applicable NCD/LCD/LCA requirements.

    Step Therapy

    Prior therapy requirement (3-month trial)

    Document a contraindication, intolerance, or clinical failure after a minimum 3-month trial on a maximum tolerated dose of xanthine oxidase inhibitors (e.g., allopurinol or febuxostat) or uricosuric agents (e.g., probenecid) before initiating Krystexxa.

    Background and Clinical Context

    Pegloticase (Krystexxa) is an intravenous urate‑lowering therapy indicated for chronic gout refractory to conventional therapy. The agent is immunogenic and associated with infusion reactions and anaphylaxis; baseline eligibility requires adult candidacy (≥18 years) and the absence of FDA‑labeled contraindications.

    Definitions and Notes

    Clinical failure
    DefinitionInability to reduce serum uric acid to < 6 mg/dL during a minimum 3-month trial on maximum tolerated dose of xanthine oxidase inhibitors or uricosuric agents.
    Required trial durationMinimum 3-month trial on prior therapy at maximum tolerated dose
    Prior therapies referencedExamples include xanthine oxidase inhibitors (allopurinol, febuxostat) or uricosurics (probenecid)
    Retreatment risk note
    Evidence gapNo controlled trial data available on safety and efficacy of re-treatment after stopping treatment for longer than 4 weeks.
    Safety concernRetreatment after a drug-free interval may increase risk of anaphylaxis and infusion reactions.

    Policy Revision History

    2013-02-07policy_origin

    Policy originated (date of origin recorded).

    2013-11-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2014-08-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    Policy Summary
    Payereocco
    PolicyKrystexxa (pegloticase) (Intravenous) — Coverage Criteria
    Policy CodePolicy IC-0158
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization with documentation of baseline serum uric acid ≥ 7 mg/dL; initial approval is valid for 6 months and renewals up to 12 months with labs showing serum uric acid ≤ 6 mg/dL prior to infusion.
    SourceLink
    On This Page
    Coverage Criteria for Krystexxa (pegloticase)Billing Codes and Covered DiagnosesPrior Authorization, Documentation, and Provider RequirementsBackground and Clinical ContextDefinitions and NotesPolicy Revision History
    • Clinical failure defined as inability to reduce serum uric acid to < 6 mg/dL during the trial.
    Note
    Documentation Required

    Required serum uric acid and renewal labs

    Submit documentation of baseline serum uric acid ≥ 7 mg/dL; for renewals provide current labs demonstrating serum uric acid ≤ 6 mg/dL prior to the scheduled infusion, along with clinical documentation of response and absence of unacceptable toxicity.

    • Baseline lab report showing serum uric acid ≥ 7 mg/dL is required for initial approval.
    • For renewal, provide current serum uric acid ≤ 6 mg/dL prior to scheduled infusion and evidence of disease response.
    Documentation Required

    Support covered diagnosis with Appendix 1 code

    Documentation must support one of the ICD-10 diagnosis codes listed in Appendix 1 to establish a covered indication for Krystexxa.

    Denial Risk

    Denial triggers: age, contraindications, missing baseline UA

    Requests may be denied if the member is under 18 years of age, has an FDA-labeled contraindication to Krystexxa (e.g., G6PD deficiency or prior serious hypersensitivity), or lacks documentation of baseline serum uric acid ≥ 7 mg/dL.

    • Examples of FDA-labeled contraindications include G6PD deficiency and history of serious hypersensitivity to Krystexxa or its components.
    Denial Risk

    Renewal denial risks: toxicity or inadequate uric acid control

    Renewal requests may be denied for unacceptable toxicity (examples: anaphylaxis, infusion reactions, exacerbation of congestive heart failure, hemolytic reactions) or if documentation does not show serum uric acid ≤ 6 mg/dL prior to the scheduled infusion.

    • Provide documentation that there is absence of unacceptable toxicity and that continuation is necessary to maintain response/remission.
    Note

    Comply with Medicare NCDs/LCDs/LCAs for Medicare members

    Follow applicable Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) where relevant; noncompliance with these Medicare policies may affect coverage determinations for Medicare members.

    • Use the CMS Coverage Database to search for relevant NCDs/LCDs/LCAs: https://www.cms.gov/medicare-coveragedatabase/search.aspx.
    Monitoring recommendationMembers receiving retreatment after >4 weeks should be monitored carefully for infusion-related and hypersensitivity reactions.
    Chronic gout due to renal impairment / Other secondary chronic gout (selected ICD-10 codes)
    Code seriesChronic gout due to renal impairment and other secondary chronic gout — ICD-10 codes in the M1A.* series (site- and tophus-specific)
    Examples from Appendix 1M1A.3210, M1A.3211, M1A.3220, M1A.3221, M1A.3290, M1A.3291 (chronic gout due to renal impairment; various sites; with/without tophus)
    Additional covered codesAppendix 1 lists many other M1A codes including right/left/unspecified wrist, hand, hip, knee, ankle and foot, vertebrae, multiple sites, and unspecified chronic gout codes.
    2015-07-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2016-07-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2016-09-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2016-12-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2017-03-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2017-06-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2017-09-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2017-12-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2018-03-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2018-06-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2018-10-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2019-10-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2020-10-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2021-10-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2022-08-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2023-03-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2023-10-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2024-07-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2025-07-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2025-11-01reviewed

    Policy reviewed (listed among Dates Reviewed).

    2026-07-01last_reviewedLatest

    Policy last reviewed and updated (Last Review Date: 07/01/2026).